NEW YORK (GenomeWeb News) — EuroGentest is expected to announce next week that it is evaluating a pyrophosphorolysis activated polymerization assay for prenatal screening through Europe’s Special Non-invasive Advances in Fetal and NeoNatal Evaluation Network (SAFE) and another of its Excellence programs.
The PAP assay, a non-invasive prenatal screening test, uses maternal plasma to detect rare mutations and to determine fetal sex.
The SAFE program is being conducted with Network of Excellence partner the London Institute of Child Health, and with researchers from Bristol University, said Richard Hayhurst, a EuroGentest spokesperson.
EuroGeneTest is a 5-year, €10 million ($13.1 million) project involving 100 accredited labs that aims to help European labs and manufacturers evaluate new technologies.